Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xilio Therapeutics (XLO) Long-Term Debt Repayments (2024)

Xilio Therapeutics (XLO) has disclosed Long-Term Debt Repayments for 1 consecutive years, with $3.3 million as the latest value for Q1 2024.

  • Quarterly Long-Term Debt Repayments changed N/A to $3.3 million in Q1 2024 from the year-ago period, while the trailing twelve-month figure was $3.3 million through Dec 2024, changed N/A year-over-year, with the annual reading at $3.3 million for FY2024, 50.01% down from the prior year.
  • Long-Term Debt Repayments hit $3.3 million in Q1 2024 for Xilio Therapeutics.
  • In the past five years, Long-Term Debt Repayments ranged from a high of $3.3 million in Q1 2024 to a low of $3.3 million in Q1 2024.